Insider Selling: USANA Health Sciences, Inc. (NYSE:USNA) Director Sells 780 Shares of Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director Peggie Pelosi sold 780 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $28.10, for a total value of $21,918.00. Following the transaction, the director now owns 3,395 shares of the company’s stock, valued at $95,399.50. This trade represents a 18.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

USANA Health Sciences Price Performance

NYSE USNA opened at $29.97 on Tuesday. The business has a 50 day simple moving average of $33.42 and a 200 day simple moving average of $36.47. USANA Health Sciences, Inc. has a one year low of $27.71 and a one year high of $50.32. The stock has a market capitalization of $571.21 million, a P/E ratio of 10.59, a P/E/G ratio of 0.93 and a beta of 0.87.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The business had revenue of $213.61 million during the quarter, compared to analysts’ expectations of $208.82 million. Equities analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Institutional Investors Weigh In On USANA Health Sciences

Large investors have recently added to or reduced their stakes in the business. R Squared Ltd acquired a new stake in USANA Health Sciences during the fourth quarter worth approximately $28,000. Safe Harbor Fiduciary LLC acquired a new stake in USANA Health Sciences in the third quarter valued at approximately $30,000. KBC Group NV grew its stake in USANA Health Sciences by 96.6% in the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after acquiring an additional 519 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in USANA Health Sciences in the fourth quarter valued at approximately $83,000. Finally, Quantbot Technologies LP acquired a new stake in USANA Health Sciences in the fourth quarter valued at approximately $132,000. Institutional investors and hedge funds own 54.25% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on USNA shares. Sidoti downgraded USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 18th. DA Davidson lowered their price objective on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, February 27th. Finally, StockNews.com downgraded USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.